Hemington Wealth Management Purchases 27 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hemington Wealth Management grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 121 shares of the biopharmaceutical company’s stock after purchasing an additional 27 shares during the quarter. Hemington Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $86,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of REGN. Creative Planning grew its stake in shares of Regeneron Pharmaceuticals by 22.7% during the third quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after purchasing an additional 2,178 shares during the period. Kapitalo Investimentos Ltda bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $337,000. Sumitomo Life Insurance Co. grew its position in shares of Regeneron Pharmaceuticals by 81.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 3,174 shares of the biopharmaceutical company’s stock worth $3,337,000 after buying an additional 1,427 shares during the period. Transform Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals by 7.5% in the 3rd quarter. Transform Wealth LLC now owns 9,729 shares of the biopharmaceutical company’s stock valued at $10,228,000 after acquiring an additional 677 shares during the last quarter. Finally, Bfsg LLC raised its position in shares of Regeneron Pharmaceuticals by 3,352.0% in the 3rd quarter. Bfsg LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $907,000 after acquiring an additional 838 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $663.86 on Thursday. The firm has a market capitalization of $72.95 billion, a P/E ratio of 17.34, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $712.69 and its two-hundred day moving average price is $903.47. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Finally, Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.